Document Detail


Indomethacin for post-ERCP pancreatitis prophylaxis: another attempt at the Holy Grail.
MedLine Citation:
PMID:  17489783     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Acute pancreatitis continues to be the most dreaded complication after ERCP. Various risk factors for post-ERCP pancreatitis have now been recognized including patient-related, procedure-related, and operator-related factors. Numerous attempts at finding the ideal pharmacological agent for prevention of this complication have been made but nearly all drugs evaluated have failed to demonstrate clinical efficacy. Predictably, these agents have shown promise in early single-center studies but met with disappointing results when tested in larger multicenter randomized controlled trials. As the quest for the "magic bullet" continues, selecting patients with appropriate indications for ERCP and prophylactic pancreatic duct stenting in high-risk cases appears to be the best approach to averting this complication.
Authors:
Mihir S Wagh; Stuart Sherman
Related Documents :
24862633 - Health related quality of life from a prospective randomized clinical trial of robotic ...
23158173 - Adrenalectomy may improve cardiovascular and metabolic impairment and ameliorate qualit...
9481553 - Admission-discharge policies for hysteroscopic surgery: a randomised comparison of day ...
Publication Detail:
Type:  Comment; Editorial    
Journal Detail:
Title:  The American journal of gastroenterology     Volume:  102     ISSN:  0002-9270     ISO Abbreviation:  Am. J. Gastroenterol.     Publication Date:  2007 May 
Date Detail:
Created Date:  2007-05-10     Completed Date:  2007-06-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0421030     Medline TA:  Am J Gastroenterol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  984-6     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
Cholangiopancreatography, Endoscopic Retrograde / adverse effects*
Humans
Indomethacin / therapeutic use*
Pancreatitis / etiology*,  prevention & control*
Risk Factors
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal; 53-86-1/Indomethacin
Comments/Corrections
Comment On:
Am J Gastroenterol. 2007 May;102(5):978-83   [PMID:  17355281 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  pERCePtions on ERCP utilization in the United States.
Next Document:  Remission in autoimmune hepatitis: what is it, and can it ever be achieved?